Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUASENSE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Schizophrenia,Bipolar I disorder (manic, mixed, depressive episodes),Major depressive disorder (adjunctive),Bipolar maintenance therapy
Prevention of pregnancy
100 mg orally every 12 hours.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic via CYP3A4; also CYP2D6 and CYP2C9. Metabolite N-desalkylquetiapine (norquetiapine) is active.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
92–96% bound primarily to serum albumin; also binds to alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.8–1.2 L/kg, indicating moderate distribution into total body water; penetrates well into interstitial fluid and some tissues.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 75–90% (due to moderate first-pass metabolism; absorption is rapid and complete).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-50: 100 mg every 24 hours; GFR 15-29: 100 mg every 48 hours; GFR <15: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no dose adjustment; Child-Pugh B: 50 mg every 12 hours; Child-Pugh C: not recommended.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
For children aged 6-12 years: 1 mg/kg/dose (max 50 mg) every 12 hours; ages 12-18: same as adult.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Starting dose 50 mg every 12 hours; titrate based on renal function and tolerability.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Increased risk of death in elderly patients with dementia-related psychosis. Antidepressants increased risk of suicidal thinking and behavior in children, adolescents, and young adults.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Neuroleptic Malignant Syndrome,Tardive dyskinesia,Metabolic changes: hyperglycemia/diabetes, dyslipidemia, weight gain,Leukopenia/neutropenia,Seizures,Hypotension/orthostatic hypotension,Cataracts,QT prolongation
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to quetiapine or any excipients
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit juice as it may increase estrogen levels. No other significant food interactions. Take with food if gastrointestinal upset occurs.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
QUASENSE (desogestrel/ethinyl estradiol) is pregnancy category X. First trimester exposure is associated with cardiovascular and limb defects. Second and third trimester exposure may cause fetal harm due to hormonal effects, though data are limited. Contraindicated in pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and desogestrel are excreted in breast milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as use is avoided.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Quasense is a combination oral contraceptive with ethinyl estradiol and levonorgestrel. It has a 91-day extended cycle (84 active pills, 7 placebo). Prescribe for women with endometriosis or menstrual-related disorders to reduce frequency of withdrawal bleeds. Counsel that spotting/breakthrough bleeding is common in first few cycles. Contraindicated in women with history of thromboembolic events, migraine with aura, or age >35 who smoke. Monitor blood pressure and liver function. Acetaminophen and other CYP3A4 inducers may reduce efficacy; consider additional contraception during coadministration.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time; missed pills increase pregnancy risk.,Expect irregular bleeding or spotting, especially during the first 3-6 months.,Use backup contraception (e.g., condoms) if you miss pills or start a new medication that may interfere.,Do not smoke while taking this medication; smoking increases risk of blood clots and stroke.,Seek emergency care for signs of blood clot (leg pain/swelling, chest pain, sudden severe headache or vision changes).
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUASENSE vs ALYACEN 7/7/7, answered by our medical review team.
QUASENSE is a Oral Contraceptive that works by Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUASENSE and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUASENSE is: 100 mg orally every 12 hours.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUASENSE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUASENSE is classified as Category C. QUASENSE (desogestrel/ethinyl estradiol) is pregnancy category X. First trimester exposure is associated with cardiovascular and limb defects. Second and third trimester exposure m. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.